Discover
MURA
Mural Oncology plc
2.04
2 x 1.47
2 x 2.61
bid
ask
+
2.04
0.00%
04:00 PM
| Ytd | -36.65% | |
| 1y | -48.87% |
2.03
day range
2.04
2.87
52 week range
6.25
| Open | Prev Close | Low | 2.03 | High | 2.04 | Mkt Cap | 56.13M | ||
| Vol | 0.00 | Avg Vol | 154.47K | EPS | -9.02 | P/E | N/A | Forward P/E | -0.65 |
| Beta | N/A | Short Ratio | 3.85 | Inst. Own | 69.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.60 | 200-d Avg | 3.59 | 1yr Est | 16.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -1.96 | -1.87 | 0.09 | 4.59% |
| 2024-08-13 | 2024-06 | -1.9 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -1.9 | -1.86 | 0.04 | 2.11% |
| 2024-05-14 | 2024-03 | -2.66 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -2.66 | -1.84 | 0.82 | 30.83% |
| 2024-03-26 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-17 | HC Wainwright & Co. | Upgrade | Buy | |
| 2024-10-04 | Raymond James | Upgrade | Strong Buy | |
| 2024-06-28 | Rodman & Renshaw | Upgrade | Buy | |
| 2024-04-04 | Morgan Stanley | Upgrade | Overweight |
Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-13 | ALTSCHULLER SUSAN | Director | 10.00K | Purchase |
| 2024-10-30 | CUTLER ADAM D. | Chief Financial Officer | 71.44K | Sale |
| 2024-11-06 | GOODMAN VICKI L | Officer | 67.95K | Sale |
| 2024-07-17 | KESON-BROOKES MAIKEN | Officer | 43.85K | Sale |
| 2024-12-16 | LOEW CAROLINE | Chief Executive Officer | 237.63K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 1.70M | 5.59M | 9.99% |
| 2024-09-29 | Solas Capital Management, LLC | 1.27M | 4.18M | 7.46% |
| 2024-09-29 | Vanguard Group Inc | 835.59K | 2.75M | 4.91% |
| 2024-09-29 | Alta Fundamental Advisers LLC | 720.14K | 2.37M | 4.23% |
| 2024-09-29 | Prosight Management, Lp | 570.62K | 1.88M | 3.35% |
| 2024-09-29 | Newtyn Management, Llc | 570.00K | 1.88M | 3.35% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 520.28K | 1.71M | 3.06% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 236.78K | 779.00K | 1.39% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 95.41K | 313.89K | 0.56% |
| 2024-09-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 90.00K | 296.10K | 0.53% |
| 2024-08-30 | Vanguard Health Care Index Fund | 50.15K | 165.00K | 0.29% |
| 2024-09-29 | Primecap Odyssey Aggressive Growth Fund | 45.26K | 148.91K | 0.27% |